Angela N. Koehler

Angela N. Koehler

Auto-generated profile, based on publicly available information

Angela N. Koehler

Department of Biological Engineering, Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MHMadeleine Henley
Madeleine Henley
AKAngela N. Koehler
Angela N. Koehler

22 July 2022 in Science
Verified
Journal Article
Closed access
NBNatalie Boehnke
Natalie Boehnke
Joelle StraehlaJoelle Straehla
Joelle Straehla
HSHannah C. Safford
Hannah C. Safford
MKMustafa Kocak
Mustafa Kocak
MRMatthew G. Rees
Matthew G. Rees
PHPaula Hammond
Paula Hammond
To accelerate the translation of cancer nanomedicine, we used an integrated genomic approach to improve our understanding of the cellular processes that govern nanoparticle trafficking. We developed a massively parallel screen that leverages barcoded, pooled cancer cell lines annotated with multiomic data to investigate cell association patterns across a nanoparticle library spanning a range of formulations with clinical potential. We identified both materials properties and cell-intrinsic features that mediate nanoparticle-cell association. Using machine learning algorithms, we constructed genomic nanoparticle trafficking networks and identified nanoparticle-specific biomarkers. We validated one such biomarker: gene expression ofSLC46A3, which inversely predicts lipid-based nanoparticle uptake in vitro and in vivo. Our work establishes the power of integrated screens for nanoparticle delivery and enables the identification and utilization of biomarkers to rationally design nanoformulations.

1 May 2019 in Cell Chemical Biology
Verified
Journal Article
Closed access
NSNicholas B. Struntz
Nicholas B. Struntz
ACAndrew Chen
Andrew Chen
ADAnja Deutzmann
Anja Deutzmann
RWRobert M. Wilson
Robert M. Wilson
ESEric Stefan
Eric Stefan
AKAngela N. Koehler
Angela N. Koehler

1 May 2020 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
ACAndrew Chen
Andrew Chen
AKAngela N. Koehler
Angela N. Koehler

1 February 2021 in Cell Chemical Biology
Verified
Journal Article
Open access
ARAndré Richters
André Richters
SDShelby K. Doyle
Shelby K. Doyle
DFDavid B. Freeman
David B. Freeman
CLChristina Lee
Christina Lee
BLBecky S. Leifer
Becky S. Leifer
AKAngela N. Koehler
Angela N. Koehler
Castration-resistant prostate cancers (CRPCs) lose sensitivity to androgen-deprivation therapies but frequently remain dependent on oncogenic transcription driven by the androgen receptor (AR) and its splice variants. To discover modulators of AR-variant activity, we used a lysate-based small-molecule microarray assay and identified KI-ARv-03 as an AR-variant complex binder that reduces AR-driven transcription and proliferation in prostate cancer cells. We deduced KI-ARv-03 to be a potent, selective inhibitor of CDK9, an important cofactor for AR, MYC, and other oncogenic transcription factors. Further optimization resulted in KB-0742, an orally bioavailable, selective CDK9 inhibitor with potent anti-tumor activity in CRPC models. In 22Rv1 cells, KB-0742 rapidly downregulates nascent transcription, preferentially depleting short half-life transcripts and AR-driven oncogenic programs. In vivo, oral administration of KB-0742 significantly reduced tumor growth in CRPC, supporting CDK9 inhibition as a promising therapeutic strategy to target AR dependence in CRPC.

1 February 2014 in Current Opinion in Chemical Biology
Verified
Journal Article
Open access
JHJiyoung A Hong
Jiyoung A Hong
DNDylan V Neel
Dylan V Neel
DWDina Wassaf
Dina Wassaf
FCFrancisco Caballero
Francisco Caballero
AKAngela N Koehler
Angela N Koehler
High-throughput and unbiased binding assays have proven useful in probe discovery for a myriad of biomolecules, including targets of unknown structure or function and historically challenging target classes. Over the past decade, a number of novel formats for executing large-scale binding assays have been developed and used successfully in probe discovery campaigns. Here we review the use of one such format, the small-molecule microarray (SMM), as a tool for discovering protein-small molecule interactions. This review will briefly highlight selected recent probe discoveries using SMMs as well as novel uses of SMMs in profiling applications.